These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 19707308)

  • 21. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.
    Blumenschein GR; Kies MS; Papadimitrakopoulou VA; Lu C; Kumar AJ; Ricker JL; Chiao JH; Chen C; Frankel SR
    Invest New Drugs; 2008 Feb; 26(1):81-7. PubMed ID: 17960324
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma.
    Hymes KB
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):98-109. PubMed ID: 20371442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.
    Rangwala S; Zhang C; Duvic M
    Future Med Chem; 2012 Mar; 4(4):471-86. PubMed ID: 22416775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vorinostat in solid and hematologic malignancies.
    Siegel D; Hussein M; Belani C; Robert F; Galanis E; Richon VM; Garcia-Vargas J; Sanz-Rodriguez C; Rizvi S
    J Hematol Oncol; 2009 Jul; 2():31. PubMed ID: 19635146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy.
    Chung CG; Poligone B
    Curr Hematol Malig Rep; 2015 Dec; 10(4):468-76. PubMed ID: 26626770
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential Response of Mycosis Fungoides Cells to Vorinostat.
    Bordeaux ZA; Reddy SV; Lee K; Lu W; Choi J; Miller M; Roberts C; Pollizzi A; Kwatra SG; Kwatra MM
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome.
    Sanli H; Akay BN; Anadolu R; Ozcan M; Saral S; Akyol A
    J Drugs Dermatol; 2011 Apr; 10(4):403-8. PubMed ID: 21455551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas.
    Khan O; La Thangue NB
    Nat Clin Pract Oncol; 2008 Dec; 5(12):714-26. PubMed ID: 18839006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aminosuberoyl hydroxamic acids (ASHAs): a potent new class of HDAC inhibitors.
    Belvedere S; Witter DJ; Yan J; Secrist JP; Richon V; Miller TA
    Bioorg Med Chem Lett; 2007 Jul; 17(14):3969-71. PubMed ID: 17507219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma.
    Wozniak MB; Villuendas R; Bischoff JR; Aparicio CB; Martínez Leal JF; de La Cueva P; Rodriguez ME; Herreros B; Martin-Perez D; Longo MI; Herrera M; Piris MA; Ortiz-Romero PL
    Haematologica; 2010 Apr; 95(4):613-21. PubMed ID: 20133897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects.
    Sato A
    Onco Targets Ther; 2012; 5():67-76. PubMed ID: 22573938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.
    Tiffon C; Adams J; van der Fits L; Wen S; Townsend P; Ganesan A; Hodges E; Vermeer M; Packham G
    Br J Pharmacol; 2011 Apr; 162(7):1590-602. PubMed ID: 21198545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Romidepsin: evidence for its potential use to manage previously treated cutaneous T cell lymphoma.
    Poligone B; Lin J; Chung C
    Core Evid; 2011; 6():1-12. PubMed ID: 21468238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Romidepsin: a novel histone deacetylase inhibitor for cancer.
    Bertino EM; Otterson GA
    Expert Opin Investig Drugs; 2011 Aug; 20(8):1151-8. PubMed ID: 21699444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A brief primer on treatments of cutaneous T cell lymphoma, newly approved or late in development.
    Scheinfeld N
    J Drugs Dermatol; 2007 Jul; 6(7):757-60. PubMed ID: 17763605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
    Blackmon AL; Pinter-Brown L
    Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BCL11B-Mediated Epigenetic Repression Is a Crucial Target for Histone Deacetylase Inhibitors in Cutaneous T-Cell Lymphoma.
    Fu W; Yi S; Qiu L; Sun J; Tu P; Wang Y
    J Invest Dermatol; 2017 Jul; 137(7):1523-1532. PubMed ID: 28288848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HDAC inhibitor-based therapies and haematological malignancy.
    Stimson L; Wood V; Khan O; Fotheringham S; La Thangue NB
    Ann Oncol; 2009 Aug; 20(8):1293-302. PubMed ID: 19515748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.